Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

StemCells, Inc. Appoints Dr. Alan Trounson

Published: Thursday, July 10, 2014
Last Updated: Thursday, July 10, 2014
Bookmark and Share
Company announces appointment of Dr. Trounson to its Board of Directors.

StemCells, Inc. has announced the appointment of Alan Trounson, Ph.D. to its Board of Directors. Dr. Trounson most recently served as President of The California Institute of Regenerative Medicine (CIRM), the largest scientific funding body for stem cell research in the world.

"We are thrilled to welcome Dr. Trounson to our Board," said Martin McGlynn, president and CEO of StemCells, Inc. "His diverse background includes groundbreaking academic research in both in-vitro fertilization and stem cell science, and experience as a founder of a number of successful businesses, including the Australian Stem Cell Center. Dr. Trounson has also held several Australian government appointments, including director of the Australian Special Research Council, and has served as a member of the Prime Minister's Science, Engineering and Innovation council working group. This unique combination of leadership experiences make him a very valuable addition to our board at this transformational time for our Company."

"I am excited to join StemCells, Inc. at this juncture in its clinical development program," said Dr. Alan Trounson. "StemCells, Inc. has pioneered the discovery and development of human neural stem cells as therapeutic agents and recent interim results from both the dry age-related macular degeneration and spinal cord injury studies strongly support the Company's plans to initiate Phase II proof-of-concept studies later this year. These promising clinical results also provide evidence of the potential of their HuCNS-SC® cellular platform to address disorders of the central nervous system that have defied historical therapeutic approaches. I look forward to helping the company achieve the incredible potential that exists in their research and product pipeline."

Dr. Trounson has been the recipient of over 30 awards and distinctions for his scientific work, including pioneering work in the fields of in-vitro fertilization and stem cells. As part of his academic research, Dr. Trounson pioneered a new stem cell biology approach for the treatment of a broad range of diseases and injuries, which was awarded the first ever Australian Center of Excellence in Biotechnology grant worth $110 million dollars.

Dr. Trounson's previous academic positions include Scientific Director of Monash IVF Pty Ltd., Personal Chair in Stem Cell Science and Director of the Monash Immunology and Stem Cell Laboratories, Deputy Director/Director of the Monash Institute of Reproduction and Development, Director of the Centre of Early Human Development, Facility of Medicine, and Personal Chair of Obstetrics and Gynaecology-Pediatrics at Monash University in Melbourne, Australia.

He has founded a number of companies including Infertility Medical Center Pty Ltd./Monash IVF Pty Ltd., IVF Australia Corp/IntegraMed Corp (US), Sydney IVF Pty Ltd./Genea Pty Ltd., Maccine Pte Ltd and the Australian Stem Cell Center Ltd. He established two foundations, the Low Cost IVF Foundation for the treatment of infertile women in Africa and for the treatment of patients with HIV, to avoid vertical transmission to children and the Friends of Low Cost IVF (US). He is returning to Melbourne to continue to support international biotechnology in regenerative medicine.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

StemCells, Inc. Announces Closure of Enrollment in Phase I/II Dry AMD Trial
Phase II clinical trial to begin this year.
Tuesday, June 24, 2014
StemCells, Inc. Strengthens Senior Executive Team
Company appoints Joel Naor, Naymisha Patel and Mohammad A. El-Kalay and promote Stephen Huhn to the position of vice president.
Thursday, June 19, 2014
StemCells Inc. Advances Clinical Trial in AMD to Final Cohort
Phase I/II AMD trial on track to complete enrollment in June.
Saturday, May 24, 2014
StemCells, Inc. Appoints Greg Schiffman as Chief Financial Officer
Mr. Schiffman will join Company’s executive team, effective January 1, 2014.
Friday, November 15, 2013
StemCells Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading cause of blindness in elderly.
Thursday, June 28, 2012
StemCells Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading cause of blindness in elderly.
Thursday, June 28, 2012
StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision
HuCNS-SC(R) cells (purified human neural stem cells) found to protect host photoreceptors and preserve vision in an animal model of retinal disease.
Monday, January 30, 2012
StemCells, Inc. Announces Closing of Public Offering of Common Stock and Warrants
The company announced that it has closed its previously announced underwritten offering of an aggregate of 8,000,000 units and 8,000,000 Series B Warrants, each to purchase one unit, at a public offering price of $1.25 per unit.
Friday, December 23, 2011
Stemcells, Inc. To Present At 2011 Stem Cell Meeting
StemCells, Inc. have announced that Martin McGlynn, President and CEO, will present a business update at the 2011 Forum.
Tuesday, November 29, 2011
World’s First Neural Stem Cell Transplant in Spinal Cord Injury Patient
The transplant surgery was performed by a team of surgeons led by Dr. Raphael Guzman and Dr. K. Min.
Monday, September 26, 2011
Stemcells, Inc. Awarded CIRM Planning Grant to Pursue Preclinical Development of HuCNS-SC Cells for Alzheimer’s Disease
CIRM has approved the Company’s application for a “Disease Team Therapy Development Planning Award.”
Friday, September 02, 2011
StemCells Regains Compliance for Continued NASDAQ Global Market Listing
Company has received notification from The NASDAQ stock market that the Company has regained compliance with the minimum bid price requirement.
Friday, July 22, 2011
Stemcells, Inc. Relocates Corporate Headquarters and U.S. Research Labs
Corporate headquarters and U.S.-based research and development operations relocate to 7707 Gateway Blvd, Newark, CA 94560, USA.
Wednesday, July 20, 2011
Stemcells to Present Clinical Evidence of Long-term Survival of HuCNS-SC® Cells Following Completion of Immunosuppression Regimen
The data will be reported at the International Society for Stem Cell Research (ISSCR) 9th Annual Meeting, June 15-18 in Toronto, Ontario.
Thursday, June 16, 2011
StemCells, Inc. Reports First Quarter Financial Results and Announces Reduction in Force
Company to reduce US-based workforce by 30 percent to reduce its cash burn rate and extends financial resources to focus on advancing the clinical development of HuCNS-SC® cells.
Friday, May 06, 2011
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Atmosphere Acidity Minimised to Preindustrial Levels
Sheet ice study shows acidic pollution of the atmosphere has now almost returned to preindustrial levels.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Culex Mosquitoes Do Not Transmit Zika
A study of the Culex species mosquito appears to show that the species does not transmit Zika virus.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
“Sixth Sense” More Than a Feeling
NIH study of rare genetic disorder reveals importance of touch and body awareness.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Potential of New Insect Control Traits in Agriculture
Researchers have discovered a protein that shows promise as an alternate corn rootworm control mechanism.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!